Balstilimab

Modify Date: 2024-01-19 23:07:36

Use of Balstilimab

Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1[1].

Name	Balstilimab

Description	Balstilimab (AGEN2034) is a fully human monoclonal IgG4 antibody against PD-1[1].
Related Catalog	Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1 Research Areas >> Inflammation/Immunology
In Vitro	Balstilimab (AGEN2034) 高亲和力地、选择性地结合 PD-1，并通过阻断 PD-L1 和 PD-L2 与 PD-1 结合从而增强 T 细胞的反应性[1]。
References	[1]. Drouin E E, et al. AGEN1884, an IgG1 anti-CTLA-4 antibody, combines effectively with PD-1 blockade in primary human T cell assays and in a non-human primate pharmacodynamic (PD) model. Cancer Research, 2017, 77(13_Supplement): 3654-3654.

No Any Chemical & Physical Properties